Friday, July 8, 2016, 34 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $949.85 to $17,806,365.00.

Highlighted Stocks Traded by Insiders:

Apogee (APOG) - FREE Research Report

Manning John Terence, who is Director at Apogee, sold 4,000 shares at $46.17 on July 8, 2016. Following this transaction, the Director owned 27,988 shares meaning that the stake was reduced by 12.5% with the 4,000-share transaction.

The shares most recently traded at $46.18, up $0.01, or 0.02% since the insider transaction. Historical insider transactions for Apogee go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 2,500
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 2,500
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 4,500

The average volume for Apogee has been 267,000 shares per day over the past 30 days. Apogee has a market cap of $1.3 billion and is part of the industrial goods sector and materials & construction industry. Shares are up 6.87% year-to-date as of the close of trading on Friday.

Apogee Enterprises, Inc. designs and develops glass solutions for enclosing commercial buildings and framing art in the United States, Canada, and Brazil. The stock currently has a dividend yield of 1.09%. The company has a P/E ratio of 19.0. Currently, there is 1 analyst who rates Apogee a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on APOG - FREE

TheStreet Quant Ratings rates Apogee as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and notable return on equity. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full Apogee Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Eli Lilly and (LLY) - FREE Research Report

Lilly Endowment Inc, who is 10% Owner at Eli Lilly and, sold 225,000 shares at $79.14 on July 8, 2016. Following this transaction, the 10% Owner owned 126.4 million shares meaning that the stake was reduced by 0.18% with the 225,000-share transaction.

The shares most recently traded at $79.07, down $0.07, or 0.09% since the insider transaction. Historical insider transactions for Eli Lilly and go as follows:

  • 4-Week # shares bought: 3,170
  • 4-Week # shares sold: 435,000
  • 12-Week # shares bought: 3,170
  • 12-Week # shares sold: 839,592
  • 24-Week # shares bought: 3,170
  • 24-Week # shares sold: 1.1 million

The average volume for Eli Lilly and has been 4.2 million shares per day over the past 30 days. Eli Lilly and has a market cap of $87.6 billion and is part of the health care sector and drugs industry. Shares are down 5.46% year-to-date as of the close of trading on Friday.

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The stock currently has a dividend yield of 2.57%. The company has a P/E ratio of 36.5. Currently, there are 8 analysts who rate Eli Lilly and a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LLY - FREE

TheStreet Quant Ratings rates Eli Lilly and as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full Eli Lilly and Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Synchronoss Technologies (SNCR) - FREE Research Report

Rosenberger Karen, who is EVP & Chief Financial Officer at Synchronoss Technologies, sold 787 shares at $31.45 on July 8, 2016. Following this transaction, the EVP & Chief Financial Officer owned 45,057 shares meaning that the stake was reduced by 1.72% with the 787-share transaction.

The shares most recently traded at $34.14, up $2.69, or 7.88% since the insider transaction. Historical insider transactions for Synchronoss Technologies go as follows:

  • 4-Week # shares sold: 13,000
  • 12-Week # shares sold: 26,083
  • 24-Week # shares sold: 147,336

The average volume for Synchronoss Technologies has been 351,100 shares per day over the past 30 days. Synchronoss Technologies has a market cap of $1.5 billion and is part of the technology sector and computer software & services industry. Shares are down 4.4% year-to-date as of the close of trading on Friday.

Synchronoss Technologies, Inc. provides cloud solutions and software-based activation for mobile carriers, enterprises, retailers, and original equipment manufacturers (OEMs) worldwide. The company has a P/E ratio of 67.7. Currently, there are 5 analysts who rate Synchronoss Technologies a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on SNCR - FREE

TheStreet Quant Ratings rates Synchronoss Technologies as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity. Get the full Synchronoss Technologies Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.